

-2-

Amendments to the Claims

Please amend Claims 59-60 and cancel Claims 62-63. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1-52. (Canceled)

53. (Previously Presented) A humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for $\alpha 4\beta 7$ integrin comprising a heavy chain and a light chain, wherein said heavy chain comprises the variable region of SEQ ID NO:19 and said light chain comprises the variable region of SEQ ID NO:21.
54. (Previously Presented) A method for treating inflammatory bowel disease in a patient, comprising administering to the patient an effective amount of a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for $\alpha 4\beta 7$ integrin comprising a heavy chain and a light chain, wherein said heavy chain comprises the variable region of SEQ ID NO:19 and said light chain comprises the variable region of SEQ ID NO:21.
55. (Previously Presented) The method of Claim 54 wherein said inflammatory bowel disease is ulcerative colitis.
56. (Previously Presented) The method of Claim 54 wherein said inflammatory bowel disease is Crohn's disease.
57. (Previously Presented) A humanized immunoglobulin heavy chain or antigen-binding portion thereof comprising the variable region of SEQ ID NO:19.
58. (Previously Presented) A humanized immunoglobulin light chain or antigen-binding portion thereof comprising the variable region of SEQ ID NO:21.

-3-

59. (Currently amended) A composition comprising a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for $\alpha 4\beta 7$ integrin comprising a heavy chain and a light chain, and a physiologically acceptable vehicle or carrier, wherein said heavy chain comprises the variable region of SEQ ID NO:19 and said light chain comprises the variable region of SEQ ID NO:21.
60. (Currently amended) A composition comprising a humanized immunoglobulin heavy chain or antigen-binding portion thereof comprising the variable region of SEQ ID NO:19 and a physiologically acceptable vehicle or carrier.
61. (Previously Presented) A composition comprising a humanized immunoglobulin light chain or antigen-binding portion thereof comprising the variable region of SEQ ID NO:21 and a physiologically acceptable vehicle or carrier.
- 62-63. (Canceled)